Targeted radiation zaps prostate cancer cells in new trial
NCT ID NCT06549465
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This phase 2 study tests a radioactive antibody, Ac-225 rosopatamab tetraxetan, that seeks out and delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The trial aims to find the best dose and evaluate how well the treatment shrinks tumors or lowers PSA levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a radioactive antibody called Ac-225 rosopatamab tetraxetan that targets prostate cancer cells
- What this could lead to
- If successful, this could provide a more effective treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not prove effective or may cause significant side effects from radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
-
Laura & Isaac Perlmutter Cancer Center
RECRUITINGNew York, New York, 10016, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
New York Presbyterian/Weill Cornell Medical Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
The Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
University of California San Diego
RECRUITINGSan Diego, California, 92093, United States
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63130, United States
Contact
-
X Cancer Omaha / Urology Cancer Center
RECRUITINGOmaha, Nebraska, 68130-5606, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can a Two-Drug attack stall resistant prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- Can a new daily pill slow advanced prostate cancer?
- Radiation plus hormone therapy may slow resistant prostate cancer
- Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival